Trigeminal neuralgia, commonly known as the “suicide disease”, is characterized by episodes of intense facial pain that occur when facial nerves are accidentally stimulated by routine activities such as eating or talking. Treatment options include drug therapy such as anticonvulsants and tricyclic antidepressants as well as surgical procedures like microvascular decompression and gamma knife radiosurgery. The global Trigeminal Neuralgia Treatment Market is estimation to be valued at US$ 242.95 Mn in 2023 and is expected to exhibit a CAGR of 7.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
The global Trigeminal Neuralgia Treatment Market has grown significantly in recent years due to increasing adoption of minimally invasive procedures like microvascular decompression surgery and gamma knife radiosurgery which helps relieve pain without damaging other nerves. For instance, gamma knife radiosurgery utilizes highly focused radiation beams that intersect at a focal point to treat the affected area and reduce chances of recurrence. Treatments such as microvascular decompression surgery help move the blood vessel that is pressing on the nerve away and thus preventing future attacks.
Market Dynamics
Increasing adoption of minimally invasive procedures is expected to drive the global Trigeminal Neuralgia Treatment Market growth over the forecast period. As discussed earlier, minimally invasive procedures like microvascular decompression surgery and gamma knife radiosurgery help treat TN effectively without damaging adjacent nerves and tissues. This reduces chances of recurrence of pain and minimizes risks and recovery time associated with open surgeries. Moreover, increasing awareness about Trigeminal Neuralgia condition through patient advocacy groups and availability of effective long term treatment options is also propelling the market forward. However, high cost associated with neurosurgeries and lack of definite cure for TN conditions are some factors expected to hinder the market growth.
Segment Analysis
The trigeminal neuralgia treatment market is segmented based on treatment, end-user, and distribution channel. The medical treatment sub segment dominates the market due to increasing popularity of drug therapies. Medication such as anti-seizure and antidepressant drugs are preferred as the first line of defense in trigeminal neuralgia treatment due to their non-invasive nature and cost effectiveness.
PEST Analysis
Political: Government initiatives to increase awareness about trigeminal neuralgia and research funding are helping drive market growth.
Economic: Rising healthcare spending across various countries and growing investment in neurological care are supporting market expansion.
Social: Increasing incidence of trigeminal neuralgia worldwide is necessitating improved treatment options. Growing geriatric population also fuels demand.
Technological: Advancements in minimally invasive procedures like gamma knife radiosurgery and emergence of novel drug formulations are expanding treatment avenues.
Key Takeaways
The Global Trigeminal Neuralgia Treatment Market Size is expected to witness high growth over the forecast period.
Regionally, North America leads, aided by developed healthcare infrastructure and lucrative reimbursement scenario. Europe holds the second largest share supported by rising research focus. Asia Pacific exhibits potential for fastest growth due to rapidly developing healthcare sectors across nations like India and China.
Key players operating in the trigeminal neuralgia treatment market are F. Hoffmann-La Roche Ltd. (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Abbott (U.S.), Hikma Pharmaceuticals PLC (U.K.), Allergan (Ireland), Eli Lilly and Company (U.S.), Aurobindo Pharma (India), Lupin (India), SHIONOGI & Co., Ltd. (Japan), AbbVie Inc. (U.S.).
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
